WHAT’S OUR STORY?

We are on a mission to impact patients’ lives.

We have potentially groundbreaking clinical-stage therapies in development that, if approved, offer an innovative approach to essential areas of dermatology.

OUR STORY STARTED HERE

Learn more about the product furthest along in our development pipeline
clascoterone cream 1% for acne

Read more

LATEST NEWS

June 23, 2020
chevron right icon

Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne

June 18, 2020
chevron right icon

Cassiopea announces that SIX has informed it that trading of its shares is suspended pending completion of the registration of the newly created shares

chevron right icon

Cassiopea announces completion of the rights offering – gross proceeds of EUR 23.25m

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.

Winlevi is under investigation in the United States for the treatment of acne, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone cream 1% is not FDA-approved.